Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Recruiting

Brimonidine with Netarsudil & LatanoprostEvaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Sponsor:

Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

Code:

NCT07209410

Conditions

Glaucoma

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Brimonidine Tartrate Ophthalmic 0.025%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-29. This information was provided to ClinicalTrials.gov by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, on 2025-11-18.